Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


22 Items
Title  Creator  Group name  Publishing year 
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe Hofman et al. EquipePC 2023-10
Malignancy after Augmentation Enterocystoplasty: A Nationwide Study of Natural History, Prognosis and Oncogene Panel Analysis Garnier et al. EquipePC Jul 2020
Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies Solassol et al. EquipePC Jul 2019
Naevoid acanthosis nigricans or RAVEN (rounded and velvety epidermal naevus) and mosaic FGFR3 and FGFR2 mutations Bessis et al. EquipePC Dec 22, 2018
VIM-1 carbapenemase-producing Escherichia coli in gulls from southern France Vittecoq et al. EquipePC Feb 2017
Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016 Appelgren et al. EquipePC Dec 2017
High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso Ouedraogo et al. EquipePC 2016
First description of IncX3 plasmids carrying blaOXA-181 in Escherichia coli clinical isolates in Burkina Faso Ouedraogo et al. EquipePC Feb 16 2016
Evaluation of the SLOMYCO Sensititre((R)) panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates Chazel et al. EquipePC 2016
Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens Frouin et al. EquipePC 2016
Anti-heat shock protein autoantibody profiling in breast cancer using customized protein microarray Shi et al. EquipePC Dec 29 2016
An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma Mange et al. EquipePC May 7 2016
Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy Bourgier et al. EquipePC Mar 2015
High prevalence of SXT/R391-related integrative and conjugative elements carrying blaCMY-2 in Proteus mirabilis from gull isolates in the South of France Aberkane et al. EquipePC Dec 7 2015
Establishment and characterization of a cell line from human circulating colon cancer cells Cayrefourcq et al. EquipePC Mar 1 2015
Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas(R) 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting Mourah et al. EquipePC 2015
Use of autoantibodies to detect the onset of breast cancer Lacombe et al. EquipePC 2014
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network Beau-Faller et al. EquipePC Jan 2014
Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection Frouin et al. EquipePC 2014
Comparative evaluation of the new FDA approved THxID-BRAF test with High Resolution Melting and Sanger sequencing Marchant et al. EquipePC 2014
A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women Lacombe et al. EquipePC Sep 2014
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms Beau-Faller et al. EquipePC Jan 2014
22 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés